Cell-autonomous alteration of dopaminergic transmission by wild type and mutant (ΔE) TorsinA in transgenic mice

Neurobiology of Disease

Volumn 39, Issue 3, 2010, Pages 318-326

  Page, Michelle E ^a   Bao, Li ^b   Andre, Pierrette ^a   Pelta Heller, Joshua ^a   Sluzas, Emily ^a   Gonzalez Alegre, Pedro ^c   Bogush, Alexey ^a   Khan, Loren E ^d   Iacovitti, Lorraine ^a   Rice, Margaret E ^b   Ehrlich, Michelle E ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF IOWA   (United States)

^d MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Dopamine; Dystonia; DYT1; Microdialysis; Striatum; TorsinA; Tyrosine hydroxylase; Voltammetry

Indexed keywords

ADENOSINE TRIPHOSPHATASE; TORSINA PROTEIN; TYROSINE 3 MONOOXYGENASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE RELEASE; DOPAMINERGIC NERVE CELL; DOPAMINERGIC TRANSMISSION; DYSTONIA; LOCOMOTION; MESENCEPHALON; MOTOR DYSFUNCTION; MOUSE; MUTANT; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; TRANSGENE; TRANSGENIC MOUSE; WILD TYPE;

EID: 77954956971     PISSN: 09699961     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nbd.2010.04.016     Document Type: Article

References (55)

1. Asanuma K., Ma Y., Okulski J., Dhawan V., Chaly T., Carbon M., Bressman S.B., Eidelberg D. Decreased striatal D2 receptor binding in non-manifesting carriers of the DYT1 dystonia mutation. Neurology 2005, 64:347-349.
2. Augood S.J., Keller-McGandy C.E., Siriani A., Hewett J., Ramesh V., Sapp E., DiFiglia M., Breakefield X.O., Standaert D.G. Distribution and ultrastructural localization of torsinA immunoreactivity in the human brain. Brain Res. 2003, 986:12-21.
3. Augood S.J., Hollingsworth Z., Albers D.S., Yang L., Leung J., Breakefield X.O., Standaert D.G. Dopamine transmission in DYT1 dystonia. Adv. Neurol. 2004, 94:53-60.
4. Balcioglu A., Kim M.O., Sharma N., Cha J.H., Breakefield X.O., Standaert D.G. Dopamine release is impaired in a mouse model of DYT1 dystonia. J. Neurochem. 2007, 102:783-788.
5. Bogush A.I., McCarthy L.E., Tian C., Olm V., Gieringer T., Ivkovic S., Ehrlich M.E. DARPP-32 genomic fragments drive Cre expression in postnatal striatum. Genesis 2005, 42:37-46.
6. Breakefield X.O., Kamm C., Hanson P.I. TorsinA: movement at many levels. Neuron 2001, 31:9-12.
7. Breakefield X.O., Blood A.J., Li Y., Hallett M., Hanson P.I., Standaert D.G. The pathophysiological basis of dystonias. Nat. Rev. Neurosci. 2008, 9:222-234.
8. Bressman S.B. Dystonia: phenotypes and genotypes. Rev. Neurol. 2003, 159:849-856.
9. Brown T.B., Bogush A.I., Ehrlich M.E. Neocortical expression of mutant huntingtin is not required for alterations in striatal gene expression or motor dysfunction in a transgenic mouse. Hum. Mol. Genet. 2008, 17:3095-3104.
10. Calabresi P., Di Filippo M., Ghiglieri V., Picconi B. Molecular mechanisms underlying levodopa-induced dyskinesia. Mov. Disord. 2008, 23(Suppl. 3):S570-S579.
11. Cao S., Gelwix C.C., Caldwell K.A., Caldwell G.A. Torsin-mediated protection from cellular stress in the dopaminergic neurons of Caenorhabditis elegans. J. Neurosci. 2005, 25:3801-3812.
12. Carbon M., Niethammer M., Peng S., Raymond D., Dhawan V., Chaly T., Ma Y., Bressman S., Eidelberg D. Abnormal striatal and thalamic dopamine neurotransmission: genotype-related features of dystonia. Neurology 2009, 72:2097-2103.
13. Chen B.T., Rice M.E. Novel Ca2+ dependence and time course of somatodendritic dopamine release: substantia nigra versus striatum. J. Neurosci. 2001, 21:7841-7847.
14. (2) is a novel, endogenous modulator of synaptic dopamine release. J. Neurophysiol. 2001, 85:2468-2476.
15. Crabbe J.C., Metten P., Yu C.H., Schlumbohm J.P., Cameron A.J., Wahlsten D. Genotypic differences in ethanol sensitivity in two tests of motor incoordination. J. Appl. Physiol. 2003, 95:1338-1351.
16. Dang M.T., Yokoi F., McNaught K.S., Jengelly T.A., Jackson T., Li J., Li Y. Generation and characterization of Dyt1 DeltaGAG knock-in mouse as a model for early-onset dystonia. Exp. Neurol. 2005, 196:452-463.
17. Dang M.T., Yokoi F., Pence M.A., Li Y. Motor deficits and hyperactivity in Dyt1 knockdown mice. Neurosci. Res. 2006, 56:470-474.
18. Dupuis L., Fergani A., Braunstein K.E., Eschbach J., Holl N., Rene F., Gonzalez De Aguilar J.L., Zoerner B., Schwalenstocker B., Ludolph A.C., Loeffler J.P. Mice with a mutation in the dynein heavy chain 1 gene display sensory neuropathy but lack motor neuron disease. Exp. Neurol. 2009, 215:146-152.
19. Gainetdinov R.R., Bohn L.M., Sotnikova T.D., Cyr M., Laakso A., Macrae A.D., Torres G.E., Kim K.M., Lefkowitz R.J., Caron M.G., Premont R.T. Dopaminergic supersensitivity in G protein-coupled receptor kinase 6-deficient mice. Neuron 2003, 38:291-303.
20. Gerfen C.R. D1 dopamine receptor supersensitivity in the dopamine-depleted striatum animal model of Parkinson's disease. Neuroscientist 2003, 9:455-462.
21. Goodchild R.E., Dauer W.T. The AAA+ protein torsinA interacts with a conserved domain present in LAP1 and a novel ER protein. J. Cell Biol. 2005, 168:855-862.
22. Goodchild R.E., Kim C.E., Dauer W.T. Loss of the dystonia-associated protein torsinA selectively disrupts the neuronal nuclear envelope. Neuron 2005, 48:923-932.
23. Gordon K.L., Gonzalez-Alegre P. Consequences of the DYT1 mutation on torsinA oligomerization and degradation. Neuroscience 2008, 157:588-595.
24. Granata A., Watson R., Collinson L.M., Schiavo G., Warner T.T. The dystonia-associated protein torsinA modulates synaptic vesicle recycling. J. Biol. Chem. 2008, 283:7568-7579.
25. Granata A., Schiavo G., Warner T.T. TorsinA and dystonia: from nuclear envelope to synapse. J. Neurochem. 2009, 109:1596-1609.
26. Grundmann K., Reischmann B., Vanhoutte G., Hübener J., Teismann P., Hauser T.K., Bonin M., Wilbertz J., Horn S., Nguyen H.P., Kuhn M., Chanarat S., Wolburg H., Van der Linden A., Riess O. Overexpression of human wildtype torsinA and human DeltaGAG torsinA in a transgenic mouse model causes phenotypic abnormalities. Neurobiol. Dis. 2007, 27:190-206.
27. Hewett J.W., Zeng J., Niland B.P., Bragg D.C., Breakefield X.O. Dystonia-causing mutant torsinA inhibits cell adhesion and neurite extension through interference with cytoskeletal dynamics. Neurobiol. Dis. 2006, 22:98-111.
28. Hewett J., Johanson P., Sharma N., Standaert D., Balcioglu A. Function of dopamine transporter is compromised in DYT1 transgenic animal model in vivo. J. Neurochem. 2010, 113:228-235.
29. Kessler M.A., Yang M., Gollomp K.L., Jin H., Iacovitti L. The human tyrosine hydroxylase gene promoter. Brain Res. Mol. Brain Res. 2003, 112:8-23.
30. Kim D.S., Szczypka M.S., Palmiter R.D. Dopamine-deficient mice are hypersensitive to dopamine receptor agonists. J. Neurosci. 2000, 20:4405-4413.
31. Konakova M., Pulst S.M. Immunocytochemical characterization of torsin proteins in mouse brain. Brain Res. 2001, 922:1-8.
32. Kuczenski R., Segal D.S., Aizenstein M.L. Amphetamine, cocaine, and fencamfamine: relationship between locomotor and stereotypy response profiles and caudate and accumbens dopamine dynamics. J. Neurosci. 1991, 11:2703-2712.
33. Mangiarini L., Sathasivam K., Seller M., Cozens B., Harper A., Hetherington C., Lawton M., Trottier Y., Lehrach H., Davies S.W., Bates G.P. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 1996, 87:493-506.
34. Muraro N.I., Moffat K.G. Down-regulation of torp4a, encoding the Drosophila homologue of torsinA, results in increased neuronal degeneration. J. Neurobiol. 2006, 66:1338-1353.
35. Napolitano F., Pasqualetti M., Usiello A., Santini E., Pacini G., Sciamanna G., Errico F., Tassone A., Di Dato V., Martella G., Cuomo D., Fisone G., Bernardi G., Mandolesi G., Mercuri N.B., Standaert D.G., Pisani A. Dopamine D2 receptor dysfunction is rescued by adenosine A2A receptor antagonism in a model of DYT1 dystonia. Neurobiol. Dis. 2010, 38:434-445.
36. Nery F.C., Zeng J., Niland B.P., Hewett J., Farley J., Irimia D., Li Y., Wiche G., Sonnenberg A., Breakefield X.O. TorsinA binds the KASH domain of nesprins and participates in linkage between nuclear envelope and cytoskeleton. J. Cell Sci. 2008, 121:3476-3486.
37. Ozelius L.J., Hewett J., Page C., Bressman S., Kramer P., Shalish C., de Leon D., Brin M., Raymond D., Corey D.P., Fahn S., Risch N., Buckler A., Gusella J.F., Breakefield X.O. The early-onset torsion dystonia gene (DYT1) encodes an ATP-binding protein. Nat. Genet. 1997, 17:40-48.
38. Page M.E., Abercrombie E.D. Discrete local application of corticotropin-releasing factor increases locus coeruleus discharge and extracellular norepinephrine in rat hippocampus. Synapse 1999, 33:304-313.
39. Patel J.C., Rice M.E. Dopamine release in brain slices. Encyclopedia of Sensors 2006, 313-334. American Scientific Publishers, Stevenson Ranch, California. C.A. Grimes, E.C. Dickey, M.V. Pishko (Eds.).
40. Patel J.C., Witkovsky P., Avshalumov M.V., Rice M.E. Mobilization of intracellular calcium stores facilitates somatodendritic dopamine release. J. Neurosci. 2009, 29:6568-6579.
41. Pisani A., Martella G., Tscherter A., Bonsi P., Sharma N., Bernardi G., Standaert D.G. Altered responses to dopaminergic D2 receptor activation and N-type calcium currents in striatal cholinergic interneurons in a mouse model of DYT1 dystonia. Neurobiol. Dis. 2006, 24:318-325.
42. Pisani A., Bernardi G., Ding J., Surmeier D.J. Re-emergence of striatal cholinergic interneurons in movement disorders. Trends Neurosci. 2007, 30:545-553.
43. Quartarone A., Rizzo V., Morgante F. Clinical features of dystonia: a pathophysiological revisitation. Curr. Opin. Neurol. 2008, 21:484-490.
44. Rehders J.H., Löscher W., Richter A. Evidence for striatal dopaminergic overactivity in paroxysmal dystonia indicated by microinjections in a genetic rodent model. Neuroscience 2000, 97:267-277.
45. Rice M.E., Cragg S.J. Nicotine amplifies reward-related dopamine signals in striatum. Nat. Neurosci. 2004, 7:583-584.
46. Schank J.R., Ventura R., Puglisi-Allegra S., Alcaro A., Cole C.D., Liles L.C., Seeman P., Weinshenker D. Dopamine beta-hydroxylase knockout mice have alterations in dopamine signaling and are hypersensitive to cocaine. Neuropsychopharmacology 2006, 31:2221-2230.
47. Sharma N., Baxter M.G., Petravicz J., Bragg D.C., Schienda A., Standaert D.G., Breakefield X.O. Impaired motor learning in mice expressing torsinA with the DYT1 dystonia mutation. J. Neurosci. 2005, 25:5351-5355.
48. Shashidharan P., Good P.F., Hsu A., Perl D.P., Brin M.F., Olanow C.W. TorsinA accumulation in Lewy bodies in sporadic Parkinson's disease. Brain Res. 2000, 877:379-381.
49. Shashidharan P., Kramer B.C., Walker R.H., Olanow C.W., Brin M.F. Immunohistochemical localization and distribution of torsinA in normal human and rat brain. Brain Res. 2000, 853:197-206.
50. Shashidharan P., Sandu D., Potla U., Armata I.A., Walker R.H., McNaught K.S., Weisz D., Sreenath T., Brin M.F., Olanow C.W. Transgenic mouse model of early-onset DYT1 dystonia. Hum. Mol. Genet. 2005, 14:125-133.
51. Torres G.E., Sweeney A.L., Beaulieu J.M., Shashidharan P., Caron M.G. Effect of torsinA on membrane proteins reveals a loss of function and a dominant-negative phenotype of the dystonia-associated DeltaE-torsinA mutant. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:15650-15655.
52. Westin J.E., Vercammen L., Strome E.M., Konradi C., Cenci M.A. Spatiotemporal pattern of striatal ERK1/2 phosphorylation in a rat model of L-DOPA-induced dyskinesia and the role of dopamine D1 receptors. Biol. Psychiatry 2007, 62:800-810.
53. Wichmann T. Commentary: dopaminergic dysfunction in DYT1 dystonia. Exp. Neurol. 2008, 212:242-246.
54. Witkovsky P., Nicholson C., Rice M.E., Bohmaker K., Meller E. Extracellular dopamine concentration in the retina of the clawed frog, Xenopus laevis. Proc. Natl. Acad. Sci. U. S. A. 1993, 90:5667-5671.
55. Zhao Y., DeCuypere M., LeDoux M.S. Abnormal motor function and dopamine neurotransmission in DYT1 DeltaGAG transgenic mice. Exp. Neurol. 2008, 210:719-730.